URMC Research Network

Find People
Keyword
Last Name
 
More Search Options

Alan Katz

Concepts (149)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of pubs Most recent pub Pubs by all authors Concept score Why?
Radiosurgery
9
2006
74
2.020
Why?
Liver Neoplasms
7
2006
151
1.780
Why?
Neoplasm Metastasis
5
2006
228
1.050
Why?
Carcinoma, Hepatocellular
2
2011
68
0.980
Why?
Liver Transplantation
1
2011
237
0.660
Why?
Dose Fractionation
6
2006
60
0.490
Why?
Tumor Burden
4
2006
22
0.470
Why?
Neoplasms, Second Primary
3
1996
125
0.460
Why?
Lung Neoplasms
6
2000
439
0.450
Why?
Retrospective Studies
11
1997
2267
0.440
Why?
Breast Neoplasms
4
2000
673
0.430
Why?
Aged
22
1996
7269
0.420
Why?
Radiotherapy
2
2000
198
0.410
Why?
Aged, 80 and over
15
1997
2529
0.390
Why?
Vagina
1
2001
50
0.380
Why?
Endometrial Neoplasms
1
2001
37
0.380
Why?
Middle Aged
21
1996
9837
0.380
Why?
Brachytherapy
4
2000
111
0.370
Why?
Uterine Cervical Neoplasms
1
2001
125
0.360
Why?
Neoplasms, Radiation-Induced
1
2000
80
0.340
Why?
Carcinoma, Merkel Cell
4
1996
10
0.340
Why?
Skin Neoplasms
5
1996
229
0.340
Why?
Hodgkin Disease
1
2000
155
0.320
Why?
Female
23
1996
19838
0.310
Why?
Neoplasm Recurrence, Local
4
2000
288
0.290
Why?
Antineoplastic Combined Chemotherapy Protocols
4
1997
429
0.290
Why?
Adult
20
1996
11351
0.290
Why?
Humans
29
1996
36274
0.280
Why?
Treatment Outcome
9
1997
2615
0.280
Why?
Stereotaxic Techniques
2
2006
33
0.280
Why?
Brain Neoplasms
3
2006
281
0.270
Why?
Whole-Body Irradiation
2
2006
83
0.260
Why?
Male
19
1996
19675
0.230
Why?
Waiting Lists
1
2011
12
0.210
Why?
Cholangiocarcinoma
1
2012
13
0.210
Why?
Airway Obstruction
2
2000
38
0.200
Why?
Necrosis
1
2011
103
0.200
Why?
Bone Neoplasms
3
2006
207
0.200
Why?
Organ Size
1
2011
192
0.200
Why?
Radiotherapy Dosage
6
2000
203
0.190
Why?
Neoplasm Staging
3
2001
338
0.180
Why?
Remission Induction
2
2003
161
0.170
Why?
Sarcoma, Kaposi
2
1998
15
0.170
Why?
Feasibility Studies
2
2006
202
0.170
Why?
Thoracic Neoplasms
1
2009
19
0.170
Why?
Rectal Neoplasms
1
2010
82
0.170
Why?
Adrenal Gland Neoplasms
1
2009
35
0.170
Why?
Gene Expression Regulation, Neoplastic
1
2011
256
0.160
Why?
Neoplasms
2
1999
739
0.160
Why?
Carcinoma, Squamous Cell
2
2006
236
0.160
Why?
Radiation Injuries
2
2006
131
0.160
Why?
Survival Rate
4
2009
618
0.150
Why?
Cognition Disorders
1
2011
286
0.150
Why?
Liver
1
2011
877
0.150
Why?
Glioma
1
2008
102
0.150
Why?
Adenocarcinoma
2
2006
439
0.140
Why?
Prospective Studies
4
2008
1689
0.130
Why?
Follow-Up Studies
4
2003
1855
0.120
Why?
Tumor Markers, Biological
1
2006
229
0.120
Why?
Pilot Projects
3
2008
442
0.110
Why?
Survival Analysis
5
1996
606
0.110
Why?
Lymphatic Metastasis
4
1997
142
0.110
Why?
Etoposide
2
1997
83
0.110
Why?
Fluorouracil
2
1997
78
0.100
Why?
Bronchial Diseases
1
2001
11
0.100
Why?
Radiodermatitis
1
2001
8
0.100
Why?
Lung Diseases, Obstructive
1
2001
40
0.100
Why?
Constriction, Pathologic
1
2001
76
0.100
Why?
Dermatologic Agents
1
2001
24
0.100
Why?
Sesquiterpenes
1
2001
24
0.100
Why?
Medical Records
1
2001
124
0.090
Why?
Umbilicus
1
2000
4
0.090
Why?
Cholecystectomy
1
2000
16
0.090
Why?
Abdominal Neoplasms
1
2000
17
0.090
Why?
Gallbladder Neoplasms
1
2000
8
0.090
Why?
Fatty Acids
1
2001
97
0.090
Why?
Palliative Care
2
1999
159
0.090
Why?
Lipids
1
2001
168
0.090
Why?
Nucleic Acid Synthesis Inhibitors
1
2000
10
0.090
Why?
Anti-Inflammatory Agents, Non-Steroidal
1
2001
92
0.090
Why?
Antimetabolites, Antineoplastic
1
1999
40
0.090
Why?
Prognosis
3
1997
1083
0.090
Why?
Carcinoma
1
2000
191
0.080
Why?
Double-Blind Method
2
2010
992
0.080
Why?
Laparoscopy
1
2000
187
0.080
Why?
Melanoma
1
1999
134
0.080
Why?
Dose-Response Relationship, Radiation
2
2006
219
0.070
Why?
Treatment Failure
2
2006
128
0.070
Why?
Multivariate Analysis
3
1997
541
0.070
Why?
Israel
3
1996
38
0.060
Why?
Cisplatin
3
1997
95
0.060
Why?
Analysis of Variance
2
1997
736
0.060
Why?
Tomography, X-Ray Computed
2
2006
759
0.060
Why?
Sarcoma
1
2011
63
0.050
Why?
Head and Neck Neoplasms
1
2011
83
0.050
Why?
Esophageal Neoplasms
1
2011
75
0.050
Why?
Interleukin-8
1
2011
111
0.050
Why?
Medical Illustration
1
2010
10
0.050
Why?
Radiation Oncology
1
2010
18
0.050
Why?
Radiotherapy, Conformal
1
2010
19
0.050
Why?
Chemokine CCL2
1
2011
127
0.040
Why?
Colorectal Neoplasms
1
2011
137
0.040
Why?
Observer Variation
1
2010
144
0.040
Why?
Time Factors
2
1999
3182
0.040
Why?
Gastrointestinal Tract
1
2009
26
0.040
Why?
Interleukin-6
1
2011
339
0.040
Why?
Cohort Studies
1
2012
969
0.040
Why?
Jews
2
1996
9
0.040
Why?
Combined Modality Therapy
2
1997
486
0.040
Why?
Comorbidity
1
2009
380
0.040
Why?
Kaplan-Meier Estimate
1
2008
222
0.040
Why?
Young Adult
1
2012
1059
0.040
Why?
Disease Progression
1
2009
521
0.040
Why?
Radiotherapy, Computer-Assisted
1
2006
15
0.030
Why?
Antineoplastic Protocols
1
2006
3
0.030
Why?
Kidney
1
2009
586
0.030
Why?
Emulsions
1
2001
10
0.020
Why?
Skin Pigmentation
1
2001
13
0.020
Why?
Mastectomy, Segmental
1
2001
25
0.020
Why?
Administration, Topical
1
2001
89
0.020
Why?
Antineoplastic Agents, Hormonal
1
2001
46
0.020
Why?
Tamoxifen
1
2001
81
0.020
Why?
Iridium Radioisotopes
1
2000
15
0.020
Why?
Fiber Optic Technology
1
2000
25
0.020
Why?
Postoperative Period
1
2000
84
0.020
Why?
Bronchoscopy
1
2000
29
0.020
Why?
Mitomycin
1
1999
18
0.020
Why?
Bleomycin
1
1999
47
0.020
Why?
Carboplatin
1
1999
30
0.020
Why?
Ethnic Groups
1
2001
152
0.020
Why?
Infusions, Intravenous
1
1999
143
0.020
Why?
Administration, Oral
1
2000
308
0.020
Why?
Arabs
1
1998
2
0.020
Why?
Radiotherapy, Adjuvant
1
1999
73
0.020
Why?
Incidence
1
2001
685
0.020
Why?
Immunocompromised Host
1
1998
83
0.020
Why?
Radiotherapy, High-Energy
1
1997
24
0.020
Why?
Vincristine
1
1997
62
0.020
Why?
Neoplasms, Multiple Primary
1
1997
43
0.020
Why?
Methotrexate
1
1997
73
0.020
Why?
Doxorubicin
1
1997
107
0.020
Why?
Cyclophosphamide
1
1997
174
0.020
Why?
Sunlight
1
1996
15
0.020
Why?
Practice Guidelines as Topic
1
1999
302
0.020
Why?
Dose-Response Relationship, Drug
1
1999
1117
0.020
Why?
Sex Distribution
1
1996
160
0.020
Why?
Age Distribution
1
1996
221
0.020
Why?
Registries
1
1996
223
0.020
Why?
Adolescent
1
1999
4766
0.010
Why?

Visualizations


Katz's Networks

Concepts
_
Co-Authors
_
Same Department